Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harpur, G. D.
Right arrow Articles by Ebers, G. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harpur, G. D.
Right arrow Articles by Ebers, G. C.
NEUROLOGY 1986;36:988
© 1986 American Academy of Neurology

Hyperbaric oxygen therapy in chronic stable multiple sclerosis

Double-blind study

George D. Harpur, MD, Ralph Suke, MD, Brenda H. Bass, BScN, Martin J. Bass, MD, CCFP, Shelley B. Bull, PhD, Lionel Reese, MD, FRCP(C), John H. Noseworthy, MD, FRCP(C), George P. A. Rice, MD, FRCP(C) and George C. Ebers, MD, FRCP(C)

Departments of Family Medicine (Drs. Harpur, Suke, and M. J. Bass), Clinical Neurological Sciences (Ms. B. H. Bass and Drs. Noseworthy, Rice, and Ebers), Epidemiology & Biostatistics (Dr. Bull), and Nuclear Medicine (Dr. Reese), University of Western Ontario, London, Ontario, Canada.

We carried out a randomized, double-blind, placebo-controlled trial of hyperbaric oxygen therapy (HBO) in patients with chronic stable MS. Eighty-two patients were treated in a multiplace hyperbaric chamber with gas supplied by mask. Forty-one patients received 20 consecutive daily treatments of 100% O2 followed by 7 "booster" treatments in the next 6 months; 41 control patients received "air" (12.5% O2 at 1.75 atmospheres absolute). There was no significant difference in treatment and control groups in the Extended Kurtzke Disability scores, Kurtzke Functional scores, magnetic resonance imaging, or evoked potentials after the initial 20 treatments or after the boosters. HBO is not effective in treating chronic stable MS.

Address correspondence and reprint requests to Dr. Ebers, Department of Neurological Sciences, University Hospital, London, Ontario N6A 5A5, Canada.

Shelley Bull is a Fellow of the Ontario Ministry of Health, Health Research Personnel Development Program.

Accepted for publication November 1, 1985.




This article has been cited by other articles:


Home page
 LupusHome page
D.J. Wallace, S. Silverman, J. Goldstein, and D. Hughes
Occasional Review: Use of hyperbaric oxygen in rheumatic diseases: case report and critical analysis
Lupus, June 1, 1995; 4(3): 172 - 175.
[Abstract] [PDF]

Home page
 Neurorehabil Neural RepairHome page
B. S. Giesser
Evoked Potentials As Outcome Measures in Multiple Sclerosis
Neurorehabil Neural Repair, January 1, 1993; 7(3-4): 99 - 104.
[PDF]

Home page
 Arch NeurolHome page
E. P. Kindwall, M. P. McQuillen, B. O. Khatri, H. W. Gruchow, and M. L. Kindwall
Treatment of Multiple Sclerosis With Hyperbaric Oxygen: Results of a National Registry
Arch Neurol, February 1, 1991; 48(2): 195 - 199.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
M. R. Nuwer, G. W. Ellison, and L. W. Myers
Evoked Potentials During Multiple Sclerosis Therapeutic Trials
Arch Neurol, January 1, 1989; 46(1): 11 - 12.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.